semaglutide

Details

Key Milestones2
Call for patient/clinician input open17-Oct-24
Call for patient/clinician input closed06-Dec-24
Submission received27-Nov-24
Submission accepted11-Dec-24
Review initiated12-Dec-24
Draft CADTH review report(s) provided to sponsor for comment06-Mar-25
Deadline for sponsors comments18-Mar-25
CDA-AMC review report(s) and responses to comments provided to sponsor09-Apr-25
Expert committee meeting (initial)23-Apr-25
Draft recommendation issued to sponsorMay 05, 2025
To
May 07, 2025
Draft recommendation posted for stakeholder feedback15-May-25
End of feedback period30-May-25

Adult Classical Hodgkin Lymphoma

crovalimab

Details

Key Milestones2
Call for patient/clinician input open19-Aug-24
Call for patient/clinician input closed15-Oct-24
Submission received01-Oct-24
Submission accepted16-Oct-24
Review initiated17-Oct-24
Draft CADTH review report(s) provided to sponsor for comment08-Jan-25
Deadline for sponsors comments17-Jan-25
CDA-AMC review report(s) and responses to comments provided to sponsor13-Feb-25
Expert committee meeting (initial)26-Feb-25
Draft recommendation issued to sponsor-
Clarification:

- CDEC recommendation held pending receipt of NOC and evaluation of the finalized submission requirements.

.
Draft recommendation posted for stakeholder feedback-
End of feedback period-

daratumumab

Details

Key Milestones2
Call for patient/clinician input open19-Aug-24
Call for patient/clinician input closed15-Oct-24
Submission received01-Oct-24
Submission accepted16-Oct-24
Draft CADTH review report(s) provided to sponsor for comment17-Jan-25
Deadline for sponsors comments29-Jan-25
CDA-AMC review report(s) and responses to comments provided to sponsor28-Feb-25
Expert committee meeting (initial)12-Mar-25
Draft recommendation issued to sponsor25-Mar-25
Draft recommendation posted for stakeholder feedback03-Apr-25
End of feedback period17-Apr-25
Final recommendation issued to sponsor and drug plans02-May-25
Final recommendation posted-
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)16-May-25
CDA-AMC review report(s) posted-

pasireotide

Details

Key Milestones2
Call for patient/clinician input open19-Aug-24
Call for patient/clinician input closed15-Oct-24
Submission received02-Oct-24
Submission accepted17-Oct-24
Review initiated18-Oct-24
Draft CADTH review report(s) provided to sponsor for comment09-Jan-25
Deadline for sponsors comments20-Jan-25
CDA-AMC review report(s) and responses to comments provided to sponsor13-Feb-25
Expert committee meeting (initial)26-Feb-25
Draft recommendation issued to sponsor10-Mar-25
Draft recommendation posted for stakeholder feedback20-Mar-25
End of feedback period03-Apr-25
Clarification:

- Reconsideration: minor revisions requested by sponsor

- Request for reconsideration partially accepted

trofinetide

Details

Key Milestones2
Call for patient/clinician input open16-Aug-24
Call for patient/clinician input closed15-Oct-24
Submission received29-Oct-24
Submission accepted13-Nov-24
Review initiated14-Nov-24
Draft CADTH review report(s) provided to sponsor for comment05-Feb-25
Deadline for sponsors comments14-Feb-25
CDA-AMC review report(s) and responses to comments provided to sponsor13-Mar-25
Expert committee meeting (initial)26-Mar-25
Draft recommendation issued to sponsor09-Apr-25
Draft recommendation posted for stakeholder feedback17-Apr-25
End of feedback period05-May-25

omaveloxolone

Details

Key Milestones2
Call for patient/clinician input openAugust 14, 2024
Call for patient/clinician input closedOctober 07, 2024
Submission receivedOctober 02, 2024
Submission acceptedOctober 17, 2024
Review initiatedOctober 18, 2024
Draft CADTH review report(s) provided to sponsor for commentJanuary 09, 2025
Deadline for sponsors commentsJanuary 20, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorFebruary 13, 2025
Expert committee meeting (initial)February 26, 2025
Draft recommendation issued to sponsorMarch 18, 2025
Draft recommendation posted for stakeholder feedbackMarch 27, 2025
End of feedback periodApril 10, 2025
Clarification:

- Reconsideration: major and minor revisions requested by sponsor